APVO - Aptevo Therapeutics: IXINITY Might Prove To Be A Never Expiring Option On The Company's Core Pipeline
Unfortunately, small and micro-cap stocks sometimes correct on no news in a risk-off environment, even when they have everything going for them. Such is the case for the recent correction of Aptevo Therapeutics (APVO).
The stock is a gem in the micro-cap biotech space, because it's one of the few companies of its size to have a robust pipeline (in the immuno-oncology space that might be worth billions in the future) and a marketed drug at the same time.
Today, I want to focus on a recent press release the company put out